Federal Register #E2722007

NCI Seeks Licensees for C8166-45 Human T-cell Line for Research and Development

The National Cancer Institute (NCI), part of the National Institutes of Health under the Department of Health and Human Services, is offering a government-owned human T-cell line for non-exclusive licensing. - Government Buyer: - National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (HHS) - Product Offered: - C8166-45 Human T-cell Line (also known as C63/CRII-2) - Part Number: E2722007 - Quantity: Not specified (licensing opportunity) - Description: Human T-cell line transformed by HTLV-1, containing three transcriptionally active proviruses - Key Features and Applications: - Highly permissive to HIV-1 infection - Suitable for replication-competent lentiviral assays (important for gene therapy product safety) - Valuable for research into T-cell immortalization, viral protein interactions, and HIV replication - Potential applications in cancer immunotherapy and dendritic cell-based vaccine development - Enhanced antigen-presenting function and anti-tumor efficacy - Unique Requirements: - Non-exclusive licensing of a government-developed research material - No commercial OEMs or vendors involved; the cell line is government-owned and developed - Intended Audience: - Research organizations, biotechnology companies, and parties interested in cancer immunotherapy or gene therapy safety assays

Description

The National Cancer Institute (NCI) is seeking licensees for a human T-cell line, C8166-45, which is transformed by HTLV-1. This cell line contains three transcriptionally active proviruses and is useful for testing biological activities involved in T-cell immortalization and growth. The cell line is highly permissive to HIV-1 infection and is suitable for replication-competent lentiviral assays to assess safety for gene therapy products. It is intended for research in viral protein interactions, T-cell immortalization, and HIV replication. NCI is offering this cell line for non-exclusive licensing to interested parties.

View original listing